![]() There were no statistically significant differences between treatment arms for PFS or OS. Grade ⩾3 adverse events were more common with cediranib 30 mg (91.8%) vs cediranib 20 mg (81.4%) or bevacizumab (84.8%). ![]() There were no statistically significant differences between treatment arms for PFS (cediranib 20 mg vs bevacizumab: HR=1.28 (95% CI, 0.85–1.95 P=0.29) cediranib 30 mg vs bevacizumab: HR=1.17 (95% CI, 0.77–1.76 P=0.79)) or overall survival (OS). Median PFS in the cediranib 20 mg, cediranib 30 mg and bevacizumab groups was 5.8, 7.2 and 7.8 months, respectively. Results:Ī total of 210 patients were included in the intent-to-treat (ITT) analysis (cediranib 20 mg, n=71 cediranib 30 mg, n=73 bevacizumab, n=66). The primary objective was to compare progression-free survival (PFS) between treatment arms. Patients with mCRC who had progressed following first-line therapy were randomised 1 : 1 : 1 to modified (m)FOLFOX6 plus cediranib (20 or 30 mg day −1) or bevacizumab (10 mg kg −1 every 2 weeks). Bevacizumab is an anti-VEGF-A monoclonal antibody with clinical benefit in previously treated metastatic colorectal cancer (mCRC). Cediranib is a highly potent inhibitor of vascular endothelial growth factor (VEGF) signalling with activity against all three VEGF receptors.
0 Comments
Leave a Reply. |